Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-08-21
1998-07-14
Woodward, Michael P.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514550, A01N 4378
Patent
active
057804893
ABSTRACT:
The invention provides a method for treating amyotrophic lateral sclerosis in a patient which comprises administering to the patient an effective amount of a non-cysteine glutathione precursor or a glutathione derivative so as to increase the intracellular glutathione levels and alleviate a symptom of amyotrophic lateral sclerosis. The non-cysteine substrate may be a thiazolidine-4-carboxylate analog, a thiazolidine-4-carboxylate analogs ester, or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4335210 (1982-06-01), Meister et al.
patent: 4434158 (1984-02-01), Meister et al.
patent: 4438124 (1984-03-01), Meister et al.
patent: 4647571 (1987-03-01), Meister et al.
patent: 4665082 (1987-05-01), Meister et al.
patent: 4879370 (1989-11-01), Meister
patent: 5093478 (1992-03-01), Griffith et al.
patent: 5208249 (1993-05-01), Rowe et al.
patent: 5403861 (1995-04-01), Goldin et al.
patent: 5447712 (1995-09-01), White et al.
patent: 5464825 (1995-11-01), Anderson et al.
Anderson et al., 1985, "Glutathione Monoethyl Ester: Preparation, Uptake by Tissues, and Conversion to Glutathione", Arch. Biochem. Biophys. 239:538-548.
Anderson and Meister, 1989, "Marked Increase of Crysteine Levels in Many Regions of the Brain After Administration of 2-Oxothiazolidine-4-Carboxylate", FASEB J. 3:1632-1636.
Bensimon et al., 1994, "A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis", N. Eng. J. Med. 330:585-591.
Bernard et al., 1984, "Effect of N-Acetylcysteine on the Pulmonary Response to Endotoxin in the Awake Sheep and upon In Vitro Granulocyte Function", J. Clin. Invest. 73:1772-1784.
Borchelt et al., 1995, "Superoxide Dismutase 1 Subunits with Mutations Linked to Familial Amyotrophic Lateral Sclerosis Do Not Affect WIId-Type Subunit Function", J. Biol. Chem. 270:3234-3238.
Bowling et al., 1993, "Superoxide Dismutase Activity, Oxidative Damage and Mitochondrial Energy Metabolism in Familial and Sporadic-Amyotrophic Lateral Sclerosis", J. Neurochem. 61:2322-2325.
Deng et al., "Amyotrophic Lateral Sclerosis and Structural Defects in Cu,Zn Superoxide Dismutase", Science 261:1047-1051.
Levy et al., 1993, "Transport of Glutathione Diethyl Ester into Human Cells", Proc. Natl. Acad. Sci USA 90:9171-9175.
Louwerse et al., 1995, "Randomized, Double-Blind, Controlled Trial of Acetylcysteine in Amyotrophic Lateral Sclerosis", Arch. Neurol. 52:559-564.
Meister and Anderson, 1983, "Glutathione", Ann. Rev. Biochem. 52:711-760.
Meister et al., 1986, "Intracellular Cysteine and Glutathione Delivery Systems", J. Am. Coll. Nutr. 5:137-151.
Mesina et al., 1989, "Administration of L-2-Oxothiazolidine-4-Carboxylate Increases Glutathione Levels in Rat Brain", Brain Res. 478:181-183.
Olsson et al., 1988, "Pharmacokinetics and Bioavailability of Reduced and Oxidized N-Acetylcysteine", Eur. J. Pharmacol. 34:77-82.
Puri and Meister, 1983, "Transport of Glutathione, as .gamma.-Glutamylcysteinylglycyl Ester, Into Liver and Kidney", Proc. Natl. Acad. Sci. USA 80:5258-5260.
Rosen et al., 1993, "Mutations in Cu/Zn Superoxide Dismutase Gene are Associated with Familial Amyotrophic Lateral Sclerosis", Nature 362:59-62.
Rothstein et al., 1992, "Decreased Glutamate Transport by the Brain and Spinal Cord in Amyotrophic Lateral Sclerosis", N. Eng. J. Med. 326:1464-1468.
Rothstein et al., "Chronic Inhibition of Glutamate Uptake Produces a Model of Slow Neurotoxicity", Proc. Natl. Acad. Sci. USA 90:6591-6595.
Rothstein et al., 1994, "Chronic Inhibition of Superoxide Dismutase Produces Apoptotic Death of Spinal Neurons", Proc. Natl. Acad. Sci. USA 91:4155-4159.
Shikama et al., 1995, "Transport and Metabolism of Glutathione Isoproply Ester in Cerebrospinal Fluid", Res. Comm. in Mol. Pathol. and Pharmacol. 88:349-357.
Taylor et al., 1992, "Elevation of Lung Glutathione by Oral Supplementation of L-2-Oxythiazolidine-4-Carboxylate Protects Against Oxygen Toxicity in Protein-Energy Malnourished Rats", FASEB J. 6:3101-3107.
Tsan et al., 1989, "Modulation of Endothelial GSH Concentrations: Effect of Exogenous GSH and GSH Monoethyl Ester", J. Appl. Physiol. 66:1029-1034.
Williamson and Meister, 1981, "Stimulation of Hepatic Glutathione Formation by Administration of L-2-Oxythiazolidine-4-Carboxylate, a 5-Oxo-L-Prolinase Substrate", Proc. Natl. Acad. Sci. USA 78:936-939.
Williamson et al., 1982, "Intracellular Cysteine Delivery System that Protects Against Toxicity by Promoting Glutathione Synthesis", Proc. Natl. Acad. Sci. USA 79:6246-6249.
Applied Genetic News, "ALS treated with glutathione booster", vol. 16, No. 9, p. 9, Dec. 1995.
Kalayjian et al., "A phase I/II trial of intraveneous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asymptomatic HIV-infected subjects", J. Acquir Immune Defic Syndr, vol. 7, No. 4, pp. 369-374, Apr. 1994.
Minhas et al., "Comparison of the delivery of reduced glutathione into P388D cells by reduced glutathione and its mono-and diethyl ester derivatives", Biochemical Pharmacology 1995, vol. 49, pp. 1475-1482, 1995.
Stedman's Medical Dictionary, 24th ed., Williams & Wilkins, Baltimore, p. 1264, 1982.
Brumback Brenda G.
Woodward Michael P.
LandOfFree
Method for treating amyotrophic lateral sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating amyotrophic lateral sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating amyotrophic lateral sclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1882127